Journal of Clinical Microbiology, December 2000, p. 4373-4381, Vol. 38, No. 12
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Department of Pathobiological Sciences, School of Veterinary Medicine,1 and Department of Clinical Gastroenterology and Department of Medicine4 and Department of Surgery,6 Medical School, University of Wisconsin, Madison, Wisconsin, and Department of Clinical Microbiology, Rigshospitalet,3 and Department of Clinical Microbiology2 and Department of Medical Gastroenterology,5 Herlev Hospital, Copenhagen, Denmark
Received 17 July 2000/Returned for modification 9 August 2000/Accepted 26 September 2000
Mycobacterium avium subsp. paratuberculosis
has been incriminated as a cause of Crohn's disease (CD); however,
studies to date have been relatively small and generally only used a
single diagnostic assay. The objective of the study was to reexamine the association of M. avium subsp.
paratuberculosis and CD using multiple diagnostic tests.
Five methods were used to detect M. avium subsp.
paratuberculosis infections in 439 inflammatory bowel disease (IBD) patients and 324 control subjects in the United States
and Denmark. Most assays were adaptations of diagnostic tests for this
infection performed routinely on animals. PCR for IS900, a
genetic element unique to M. avium subsp.
paratuberculosis, was positive significantly more often on
resected bowel and lymph node tissues from CD patients (19.0%) and
ulcerative colitis (UC) patients (26.2%) than from controls (6.3%)
(P < 0.05). Positive IS900 PCR results
occurred more often in U.S. than in Danish IBD patients, 32.0 versus
13.3% (P = 0.025). The majority of Danish patients
were bacillus Calmette-Guérin (Mycobacterium bovis
BCG) vaccinated (CD, 77.5%; UC, 86.6%; controls, 83.0%) whereas none of the U.S. patients with IBD and only 2% of U.S. controls were vaccinated. Among Danish IBD patients, positive PCR findings were four
times more common among subjects who were not BCG vaccinated (33.3%)
than among BCG vaccinates (8.8%, P = 0.02). Culture
of the same tissues tested by PCR using modified BACTEC 12B medium failed to grow M. avium subsp. paratuberculosis
from patients or controls. U.S. CD patients had the highest serological
evidence (enzyme-linked immunosorbent assay [ELISA] for serum
antibodies) of M. avium subsp. paratuberculosis
infection (20.7% of patients positive) which was higher than for all
UC patients studied (6.1%) or healthy controls (3.8%,
P < 0.005). Among Danish patients alone, however, no
significant differences in rates of ELISA-positive results among CD,
UC, or control patients were found. For 181 study subjects, both
IS900 PCR and ELISA were performed. Although 11 were ELISA
positive and 36 were PCR positive, in no instance was a patient
positive by both tests, suggesting that these states are mutually
exclusive. Evaluation of cytokine-mediated immune responses of IBD
patients was complicated by the influence of immunosuppressive therapy
given most IBD patients. Gamma interferon (IFN-
) release by
peripheral blood leukocytes after M. avium purified protein
derivative PPD antigen stimulation showed significantly lower responses
in CD patients than in UC patients or controls in both U.S. (by ex vivo
assay) and Danish (by in vitro assay) populations (P < 0.05). Interleukin-5 responses were not different among CD, UC, or
control groups. Collectively, the PCR, ELISA, and IFN-
tests for
M. avium subsp. paratuberculosis together with
the unexpected observation that BCG vaccination influenced M. avium subsp. paratuberculosis detection, lead us to
conclude that M. avium subsp. paratuberculosis,
or some similarly fastidious mycobacterial species, infects at least a
subset of IBD patients. Whether the infection is primary (causal)
or secondary, it may contribute to the etiopathogenesis of IBD.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|